CalciMedica Reports $7.7 Million Net Loss in Q2 2026, Sees Improvement in Financial Position

CalciMedica, Inc. reported a net loss of $7.7 million for the second quarter of 2026, compared to a net loss of $6.0 million for the same period in 2025, reflecting a 28% increase in losses year-over-year. For the first half of 2026, the company recorded a net loss of $2.7 million, a significant improvement from the $11.0 million loss reported in the first half of 2025. The company’s total operating expenses decreased by 39% to $4.0 million in the second quarter of 2026, down from $6.6 million in the prior year, primarily due to reduced research and development costs, which fell by 48% to $2.1 million.

CalciMedica's financial position showed improvement, with cash and cash equivalents increasing to $18.6 million as of June 30, 2026, up from $11.5 million at the end of 2025. The company’s total liabilities decreased significantly to $14.0 million from $20.2 million at the end of the previous fiscal year, largely due to a reduction in the warrant liability and promissory note. The company’s stockholders' equity turned positive, reaching $5.5 million, compared to a deficit of $6.6 million at the end of 2025.

Strategically, CalciMedica has been focused on advancing its clinical pipeline, particularly its lead product candidate, Auxora, a CRAC channel inhibitor. Following a recent meeting with the FDA, the company is preparing for a Phase 2b clinical trial for Auxora in acute pancreatitis, with plans to evaluate the drug's efficacy in other conditions such as pulmonary arterial hypertension. The company has also paused enrollment in its KOURAGE trial due to safety concerns but is working on protocol amendments to address these issues.

Operationally, CalciMedica has seen a decrease in research and development expenses, which were primarily driven by a reduction in preclinical and clinical trial activities. The company’s workforce has also been adjusted, with a focus on maintaining a lean operational structure while preparing for future clinical trials. As of June 30, 2026, the company had 30.7 million shares outstanding, reflecting an increase from 15.4 million shares at the end of 2025, following various financing activities including a recent PIPE financing that raised approximately $15 million.

Looking ahead, CalciMedica anticipates continued operating losses as it invests in the development of its product candidates. The company has expressed substantial doubt about its ability to continue as a going concern without additional financing, as its current cash reserves may not be sufficient to fund operations beyond the second half of 2027. The company plans to seek further funding through public and private offerings, collaborations, and licensing agreements to support its ongoing clinical development efforts.